# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wolfe Research analyst Mike Polark upgrades Insulet (NASDAQ:PODD) from Peer Perform to Outperform and announces $200 price t...
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.
2024 Outlook:Revenue Guidance (in constant currency):Guidance for the first quarter and full year 2024 reflects an estimated $2...
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, I...
Barclays analyst Matt Miksic maintains Insulet (NASDAQ:PODD) with a Equal-Weight and lowers the price target from $214 to $213.